These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1973809)

  • 1. Erythropoietin, aluminium, and anaemia in patients on haemodialysis.
    Piazza V; Galli F; Villa G; Salvadeo A; Battistel V; Barosi G
    Lancet; 1990 Jul; 336(8709):255-6. PubMed ID: 1973809
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythropoietin, aluminium, and anaemia in patients on haemodialysis.
    Zachée P; Boogaerts MA; Lins RL; Daelemans R; Henckens M; De Broe ME
    Lancet; 1990 Apr; 335(8696):1038-9. PubMed ID: 1970090
    [No Abstract]   [Full Text] [Related]  

  • 3. Erythropoietin, aluminium, and anaemia in patients on haemodialysis.
    Rosenlöf K; Fyhrquist F; Tenhunen R
    Lancet; 1990 Feb; 335(8684):247-9. PubMed ID: 1967718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminium-induced anaemia in haemodialysis patients.
    McGonigle RJ; Parsons V
    Nephron; 1985; 39(1):1-9. PubMed ID: 3969184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis.
    Piazza V; Villa G; Galli F; Segagni S; Bovio G; Poggio F; Picardi L; Salvadeo A
    Nephron; 1992; 61(1):54-7. PubMed ID: 1528341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication.
    Short AI; Winney RJ; Robson JS
    Proc Eur Dial Transplant Assoc; 1980; 17():226-33. PubMed ID: 7243773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis.
    Alfurayh O; Sobh M; Barri Y; Qunibi W; Taher S
    Nephrol Dial Transplant; 1992; 7(9):939-43. PubMed ID: 1328942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Erythropoietin today? Contrary opinions].
    Barni S; Rosti G
    Tumori; 2006; 92(1):suppl 16-23. PubMed ID: 16683392
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of anemia of chronic renal failure.
    Singh NP; Anuradha S; Chandrashekhar ; Agarwal SK
    J Assoc Physicians India; 1999 Feb; 47(2):216-23. PubMed ID: 10999096
    [No Abstract]   [Full Text] [Related]  

  • 10. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M; Sipilä R; Pitkänen E
    Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
    Fernández-Gallego J; Martín MA; Alonso A; Toledo R
    Nefrologia; 2006; 26(1):143-4. PubMed ID: 16649439
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to EPO therapy.
    Bommer J
    Przegl Lek; 1992; 49(1-2):36-7. PubMed ID: 1455003
    [No Abstract]   [Full Text] [Related]  

  • 13. Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin.
    Casati S; Castelnovo C; Campise M; Ponticelli C
    Nephrol Dial Transplant; 1990; 5(6):441-3. PubMed ID: 2122321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn.
    Wallace MR; Pybus J
    N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Does aluminum affect the effectiveness of human recombinant erythropoietin in the treatment of anemia in dialyzed patients?].
    Sulková S; Laurincová Z; Kvasnicka J
    Cas Lek Cesk; 1990 Jan; 129(4):113-5. PubMed ID: 2331725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.
    Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Vale L; Wallace S; MacLeod A
    Cochrane Database Syst Rev; 2002; (4):CD003895. PubMed ID: 12519614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.
    Stevens ME; Summerfield GP; Hall AA; Beck CA; Harding AJ; Cove-Smith JR; Paterson AD
    BMJ; 1992 Feb; 304(6825):474-7. PubMed ID: 1547417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erythropoietin resistance].
    Branger B
    Nephrologie; 2002; 23(1):3-5. PubMed ID: 11887576
    [No Abstract]   [Full Text] [Related]  

  • 19. Direct effect of deferoxamine on hemoglobin synthesis in patients on hemodialysis treated with recombinant human erythropoietin.
    Romero R; Novoa D; Otero S; Alonso MC; Alonso R; Arcocha V; Arza D; Lens XM; Sanchez-Guisande D
    Nephron; 1993; 63(2):164-7. PubMed ID: 8450906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.